Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps
Primary Purpose
Nasal Polyps
Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
budesonide
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Nasal Polyps focused on measuring nasal polyps, remodeling, inflammatory cells, budesonide
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of chronic rhinosinusitis was made on the basis of symptoms of rhinosinusitis for at least 12 weeks, confirmed by abnormalities in all sinuses on computed tomography scan.
- Bilateral nasal polyps were present.
- CRSwNP was defined as eosinophilic when percent of tissue eosinophils exceeded 10% of total infiltrating cells.
- All patients had taken no steroids or antibiotics for at least 4 weeks before sample collection.
Exclusion Criteria:
- cystic fibrosis
- pregnancy
- serious or unstable concurrent disease
- psychological disorder.
Sites / Locations
- Beijing Tongren Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
budesonide
placebo
Arm Description
Outcomes
Primary Outcome Measures
reduction of nasal polyp size
endoscopic polyp scores are assessed pre- and post-treatment.
patients' assessment of symptoms improvement
Four major symptoms, including nasal obstruction, discharge, loss of smell, headache/ facial pain, and TNSS were assessed by the patient pre- and post-treatment
Secondary Outcome Measures
immunologic effect of budesonide transnasal nebulization in CRSwNP
Polyp samples were evaluated for inflammatory cytokines, mediators and cellular infiltration pre- and post-treatment.
remodeling effect of budesonide transnasal nebulization in CRSwNP
Albumin, collagen,TGF-beta, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) were measured in tissue homogenate at baseline and after 2-week treatment
Full Information
NCT ID
NCT02024659
First Posted
December 27, 2013
Last Updated
October 9, 2014
Sponsor
Beijing Tongren Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02024659
Brief Title
Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps
Official Title
Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
January 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Tongren Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This randomized, double-blind, placebo-controlled clinical trial enrolled subjects with eosinophilic CRSwNP. Subjects were randomized to receive either budesonide inhalation suspension or placebo for 14 days. Visual analogue scales (VAS)of nasal symptoms, endoscopic polyp scores and morning serum cortical levels were assessed pre- and post-treatment. Polyp samples were evaluated for inflammatory cytokines, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by immunoassay; collagen by histochemistry; and frequencies of different inflammatory T cell infiltration by flow cytometry. this study is undertaken to evaluate the efficacy of short-term prescription of budesonide inhalation suspension via transnasal nebulization by clinical and immunologic assessments. As outcome parameters for remodeling, differences in the expression of collagen and albumin were investigated before and after budesonide treatment. Meanwhile, TGF-β, MMPs and TIMPs expression differences in nasal polyps were investigated to explore underlying mechanisms of tissue reconstitution.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nasal Polyps
Keywords
nasal polyps, remodeling, inflammatory cells, budesonide
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
57 (Actual)
8. Arms, Groups, and Interventions
Arm Title
budesonide
Arm Type
Experimental
Arm Title
placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
budesonide
Intervention Description
Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
patients receive placebo (saline solution) 2ml twice daily for 14 days.
Primary Outcome Measure Information:
Title
reduction of nasal polyp size
Description
endoscopic polyp scores are assessed pre- and post-treatment.
Time Frame
from baseline to two weeks
Title
patients' assessment of symptoms improvement
Description
Four major symptoms, including nasal obstruction, discharge, loss of smell, headache/ facial pain, and TNSS were assessed by the patient pre- and post-treatment
Time Frame
from baseline to two weeks
Secondary Outcome Measure Information:
Title
immunologic effect of budesonide transnasal nebulization in CRSwNP
Description
Polyp samples were evaluated for inflammatory cytokines, mediators and cellular infiltration pre- and post-treatment.
Time Frame
from baseline to 2 weeks
Title
remodeling effect of budesonide transnasal nebulization in CRSwNP
Description
Albumin, collagen,TGF-beta, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) were measured in tissue homogenate at baseline and after 2-week treatment
Time Frame
from baseline to 2 weeks
Other Pre-specified Outcome Measures:
Title
safety of budesonide via transnasal nebulization in nasal polyps
Description
Morning corticol level is measured pre- and post-treatment. The incidence and severity of adverse events are recorded during treatment.
Time Frame
from baseline to 2 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of chronic rhinosinusitis was made on the basis of symptoms of rhinosinusitis for at least 12 weeks, confirmed by abnormalities in all sinuses on computed tomography scan.
Bilateral nasal polyps were present.
CRSwNP was defined as eosinophilic when percent of tissue eosinophils exceeded 10% of total infiltrating cells.
All patients had taken no steroids or antibiotics for at least 4 weeks before sample collection.
Exclusion Criteria:
cystic fibrosis
pregnancy
serious or unstable concurrent disease
psychological disorder.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luo Zhang, MD
Organizational Affiliation
Beijing Institute of Otolaryngology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beijing Tongren Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
12. IPD Sharing Statement
Learn more about this trial
Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps
We'll reach out to this number within 24 hrs